umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Androgens and prostate cancer risk: a prospective study
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Urology and Andrology. null.
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Urology and Andrology. Urologi och andrologi.
null.
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Nutritional Research. null.ORCID iD: 0000-0001-9581-3845
Show others and affiliations
2007 (English)In: The Prostate, ISSN 0270-4137, E-ISSN 1097-0045, Vol. 67, no 11, 1230-1237 p.Article in journal (Refereed) Published
Abstract [en]

Background: Androgens have been implicated in prostate tumorigenesis, but prospective studies have overall reported no association between circulating levels of androgens and risk of prostate cancer. However, some recent studies have shown that a high level of testosterone increase the risk of non-aggressive tumors but is associated with a decreased risk of aggressive tumors.

Methods: We prospectively measured plasma levels of total testosterone, androstanediol glucuronide (A-diol-g) and sex hormone binding globuline (SHBG) and calculated estimated levels of free testosterone, in a nested case-control study of 392 cases and 392 matched controls.

Results: None of the studied hormones were significantly associated with prostate cancer risk in the full study group or in subgroups according to tumor aggressiveness. Odds ratios in the full study group, for top versus bottom quartile, was for total testosterone 1.25 (95% CI = 0.79–2.00; Ptrend = 0.51); free testosterone, 1.31 (95% CI = 0.82–2.07; Ptrend = 0.35); A-diol-g, 0.88 (95% CI = 0.59–1.33; Ptrend = 0.77); and for SHBG, 1.01 (95% CI = 0.64–1.58; Ptrend = 0.94).

Conclusions: We found no significant associations between androgen levels and risk of prostate cancer in this population-based, non-screened cohort.

Place, publisher, year, edition, pages
John Wiley & Sons, 2007. Vol. 67, no 11, 1230-1237 p.
Keyword [en]
Androgens, epidemiology, prospective studies, prostatic neoplasms
National Category
Public Health, Global Health, Social Medicine and Epidemiology Urology and Nephrology Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-17972DOI: 10.1002/pros.20588ISI: 000248537500010PubMedID: 17562541ISBN: (print)OAI: oai:DiVA.org:umu-17972DiVA: diva2:157645
Projects
Funder
Available from: 2008-01-10 Created: 2008-01-10 Last updated: 2017-12-14Bibliographically approved
In thesis
1. Prospective studies of hormonal and life-style related factors and risk of cancer
Open this publication in new window or tab >>Prospective studies of hormonal and life-style related factors and risk of cancer
2014 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Background: Androgens are important in prostate cancer development but how circulating levels of androgens affect risk of prostate cancer of different aggressiveness is not clear. Being childless has been associated with a lower risk of prostate cancer, but it is not clear if this association is causal or a result of residual confounding. Fathering of dizygotic twins, a marker of high fertility, has not been studied in relation to risk of prostate cancer.

Another marker of life-long hormonal exposure is height, which has been associated with increased risk of cancer and cancer death. However, the association to separate cancer sites has not been consistent.

The aims of this thesis were to study hormonal factors (paper I), and proxies of hormonal factors (paper II and III), and risk of prostate cancer; as well as height and risk of cancer and cancer death by separate sites (paper IV).

Methods: Study designs were i) case-control studies, nested within the Västerbotten Intervention Project (paper I), and in Prostate Cancer database Sweden 2.0 (PCBaSe 2.0) (paper II and III), and ii) cohort study, in the Metabolic Syndrome and Cancer project (Me-Can) (paper IV).

Results, prostate cancer: In paper I, increasing levels of serum androgens were not associated with risk of prostate cancer overall or in tumor risk categories. In paper II, childless men had a lower risk of prostate cancer, overall and in all risk categories, compared to fathers, an association which was in part explained by differences in marital status and educational level.  In paper III, fathers of dizygotic twins did not have an increased risk of prostate cancer, either overall or in risk categories, when compared to fathers of singletons.

Results, cancer overall: In paper IV, height was associated with an increased risk of cancer and cancer death overall in both women and men. The strongest association for cancer was to malignant melanoma in both women and men, and for cancer death to post-menopausal breast cancer in women and renal cell carcinoma in men.

Conclusions: These studies indicate that hormonal factors, when studied as serum levels or when studied using proxies of fertility, do not have a major impact on the risk of prostate cancer. The association between height and an increased risk of cancer appears robust for total cancer and cancer death, as well as for several separate cancer sites.

Place, publisher, year, edition, pages
Umeå: Umeå Universitet, 2014. 76 p.
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 1648
Keyword
prostate cancer, epidemiology, androgens, risk factors, fatherhood status, dizygotic twins, height, cohort, case-control, prospective
National Category
Urology and Nephrology Cancer and Oncology
Research subject
Cancer Epidemiology
Identifiers
urn:nbn:se:umu:diva-88308 (URN)978-91-7601-029-7 (ISBN)
Public defence
2014-06-05, Bergasalen, Umeå Universitetssjukhus, byggnad 27, Umeå, 09:00 (Swedish)
Opponent
Supervisors
Funder
Swedish Cancer Society, 11 0471Swedish Research Council, 825-2010-5950
Available from: 2014-05-07 Created: 2014-04-30 Last updated: 2014-12-09Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wirén, SaraStocks, TanjaHallmans, GöranBergh, AndersStattin, Pär
By organisation
Urology and AndrologyNutritional ResearchPathology
In the same journal
The Prostate
Public Health, Global Health, Social Medicine and EpidemiologyUrology and NephrologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 93 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf